Vendor scorecard

Calibrate

68/100
Routable
United States · Telehealth (50 states) · US telehealth · brand-only GLP-1 formulary (Wegovy + Zepbound + Foundayo oral) with insurance-first navigation + year-long structured metabolic-health program

Calibrate scored 68/100 on Panya's 11-signal vendor rubric. Each signal is scored 0 to 100, the methodology is public, and our affiliate posture is flat-fee · never pay-to-rank. Below is the full per-signal breakdown.

Visit Calibrate →Read the rubricGet your match
11-signal breakdown
  • COA on every lot
    Brand pharmacy supply only; QC at manufacturer level
    85
  • Cold-chain verified
    80
  • Rx legality
    FDA-approved-only formulary; no compounded exposure to the April 30 503B-exclusion proposal. Year-long enrollment model with documented diagnosis + Rx workflow
    90
  • Compound identity
    85
  • Dose accuracy
    85
  • Endotoxin testing
    80
  • Refund posture
    3-month upfront commitment ($597); month-to-month after; refund process clinic-mediated
    65
  • Channel clarity
    Insurance navigation + appeals support is core differentiator; ~$25/mo branded GLP-1 copays for many commercial-plan members. Cash-pay Foundayo $149/mo from April 2026 launch
    85
  • Support quality
    Coaching across food, sleep, exercise, emotional health; year-long metabolic-health framing rather than pure-Rx-fulfillment
    80
  • Price transparency
    Program $199/mo (down from $299), medication separate via insurance or cash; structure published pre-checkout
    70
  • Longitudinal retention
    Year-long program design + insurance integration support continuity over the typical 12-18 month GLP-1 weight-management horizon
    70
Supply where Calibrate operates
Mounjaro
Stable

Brand pharmacy supply stable. Compounded channel sunsetting · April 30, 2026 FDA proposal to exclude tirzepatide from the 503B bulks list (comment closes June 29, final rule likely Q3 2026) closes the mass-compounded path. 503A patient-specific compounding survives only with documented medical necessity. Telehealth platforms (Hims, Ro, Mochi) pivoting toward brand prescriptions or oral alternatives.

0d ago
Ozempic
Stable

Recovered from the 2023 shortage. Diabetes-coded insurance straightforward.

1w ago
Rybelsus
Stable

Oral semaglutide. Niche fit for needle-averse patients. Lower bioavailability than injectable.

1w ago
Wegovy
Stable

Recovered from the 2023-24 shortage. Insurance coverage expanding under 2025-26 employer plans. Oral Wegovy 25mg launched Jan 2026 at $149/mo · adds a needle-free path. Compounded semaglutide channel similarly narrowing under post-Feb-2025 enforcement-discretion rules.

0d ago
Zepbound
Stable

Lilly-direct LillyDirect channel (US-only) supplements pharmacy distribution. Stable. Brand-channel demand expected to lift through 2026 as compounded pathway closes under the April 30 FDA 503B-exclusion proposal · LillyDirect's at-launch pricing materially undercuts compounded for patients without insurance coverage.

0d ago
Full supply tracker across all regions →
Sources we audited against
How we score

The 11-signal rubric is public.

Identity, dose accuracy, COA, cold-chain, Rx legality, compound identity, endotoxin testing, refund posture, channel clarity, support quality, price transparency, longitudinal retention. Each scored 0 to 100. Vendors that fail our floor are silently filtered out · they don't appear in our match flow at all.

If Calibrate wants to dispute or update this score, contact partner@panya.health. Score updates are recorded on this page with a public changelog.

Full methodology →

Want a match for your situation?

Take the 2-minute quiz. We'll match you against this and the other vendors in your region · based on your dose, urgency, and budget.

Take the quiz

We earn a small commission when you buy through recommended vendors. That is how this stays free. Vendors rank by quality signals, not paid placement.